Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-090592 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): itraconazole (HOS-084516) telithromycin (HOS-084523) clarithromycin (HOS-084517) rifampin (HOS-088791) rifabutin (HOS-086262) ketoconazole (HOS-084513) voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-090595 · Präparat HOS-084095
Ketoconazole (CYP3A4 inhibitor)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage ce5dc75ae810b931dc151756c23881bc1d079deafb4e8e079228b7bdeb954017 · Zeichen 1162–1193 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-090596 · Präparat HOS-084095
Multiple-dose ketoconazole administration significantly affected the rate and extent of absorption and
sirolimus exposure from Rapamune oral solution as reflected by increases in sirolimus C max, tmax, and
AUC of 4.4-fold, 1.4-fold, and 10.9-fold, respectively. Co-administration of sirolimus and
ketoconazole is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage f093aee2fede9df4671904db3184ee26b0302e598c7f6799829e53e13ab4d4df · Zeichen 1195–1542 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090664 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) rifampin (HOS-088791) rifabutin (HOS-086262) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) telithromycin (HOS-084523)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090667 · Präparat HOS-084095
Ketoconazole (CYP3A4 inhibitor)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage ce5dc75ae810b931dc151756c23881bc1d079deafb4e8e079228b7bdeb954017 · Zeichen 1162–1193 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090668 · Präparat HOS-084095
Multiple-dose ketoconazole administration significantly affected the rate and extent of absorption and
sirolimus exposure from Rapamune oral solution as reflected by increases in sirolimus C max, tmax, and
AUC of 4.4-fold, 1.4-fold, and 10.9-fold, respectively. Co-administration of sirolimus and
ketoconazole is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage f093aee2fede9df4671904db3184ee26b0302e598c7f6799829e53e13ab4d4df · Zeichen 1195–1542 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 300 mg/0.5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5–6
HOS-130699 · Präparat HOS-096947
Netupitant is mainly metabolised by CYP3A4; therefore, co-administration with medicinal products
that inhibit or induce CYP3A4 activity may influence plasma concentrations of netupitant.
Consequently, concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole)
should be approached with caution and concomitant administration with strong CYP3A4 inducers
(e.g., rifampicin) should be avoided. Moreover, this medicinal product should be used with caution in
patients receiving concomitant orally administered active substances with a narrow therapeutic range
that are primarily metabolised by CYP3A4, such as cyclosporine, tacrolimus, sirolimus, everolimus,
5
alfentanil, diergotamine, ergotamine, fentanyl, and quinidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) cyclosporine (HOS-084512) tacrolimus (HOS-085202) sirolimus (HOS-085172) everolimus (HOS-086310) alfentanil (HOS-109375) ergotamine (HOS-086154) fentanyl (HOS-086196) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage feff48dcbd1e3a397dca67ff11c9be3c5588e9ca8708f2aed816cac8522d3598 · Zeichen 3768–4558 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 235 mg/0.25 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 21–22
HOS-130740 · Präparat HOS-096947
Netupitant is mainly metabolised by CYP3A4; therefore, co-administration with medicinal products
that inhibit or induce CYP3A4 activity may influence plasma concentrations of netupitant.
Consequently, concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole) should
21
be approached with caution and concomitant administration with strong CYP3A4 inducers (e.g.,
rifampicin) should be avoided. Moreover, this medicinal product should be used with caution in
patients receiving concomitant orally administered active substances with a narrow therapeutic range
that are primarily metabolised by CYP3A4, such as cyclosporine, tacrolimus, sirolimus, everolimus,
alfentanil, diergotamine, ergotamine, fentanyl, and quinidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) cyclosporine (HOS-084512) tacrolimus (HOS-085202) sirolimus (HOS-085172) everolimus (HOS-086310) alfentanil (HOS-109375) ergotamine (HOS-086154) fentanyl (HOS-086196) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 6d43f4270698847344eb1b734abf13ad2bf8f680bba27f36d2af8f239618c6f4 · Zeichen 3798–4588 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 235 mg/0.25 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 39–40
HOS-130783 · Präparat HOS-096947
Netupitant is mainly metabolised by CYP3A4; therefore, co-administration with medicinal products
that inhibit or induce CYP3A4 activity may influence plasma concentrations of netupitant.
Consequently, concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole) should
39
be approached with caution and concomitant administration with strong CYP3A4 inducers (e.g.,
rifampicin) should be avoided. Moreover, this medicinal product should be used with caution in
patients receiving concomitant orally administered active substances with a narrow therapeutic range
that are primarily metabolised by CYP3A4, such as cyclosporine, tacrolimus, sirolimus, everolimus,
alfentanil, diergotamine, ergotamine, fentanyl, and quinidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) cyclosporine (HOS-084512) tacrolimus (HOS-085202) sirolimus (HOS-085172) everolimus (HOS-086310) alfentanil (HOS-109375) ergotamine (HOS-086154) fentanyl (HOS-086196) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 39f90840a2362fc69f04f921682545e70a0354d1c40c395de423a823b9c589e3 · Zeichen 3799–4589 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 300 mg/0.5 mg oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 56
HOS-130819 · Präparat HOS-096947
Netupitant is mainly metabolised by CYP3A4; therefore, co-administration with medicinal products
that inhibit or induce CYP3A4 activity may influence plasma concentrations of netupitant.
Consequently, concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole)
should be approached with caution and concomitant administration with strong CYP3A4 inducers
(e.g., rifampicin) should be avoided. Moreover, this medicinal product should be used with caution in
patients receiving concomitant orally administered active substances with a narrow therapeutic range
that are primarily metabolised by CYP3A4, such as cyclosporine, tacrolimus, sirolimus, everolimus,
alfentanil, diergotamine, ergotamine, fentanyl, and quinidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) cyclosporine (HOS-084512) tacrolimus (HOS-085202) sirolimus (HOS-085172) everolimus (HOS-086310) alfentanil (HOS-109375) ergotamine (HOS-086154) fentanyl (HOS-086196) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage e20102f3d8095f1dd05c59d29ef1fcf01bb3e4788261fb2373293f9a27f0cc6d · Zeichen 3761–4497 im Abschnitt
Gegenanzeigen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.3 · PDF-Seite 4–5
HOS-132835 · Präparat HOS-097310
4
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations
of these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions;
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147) irinotecan (HOS-112102) everolimus (HOS-086310) sirolimus (HOS-085172) vardenafil (HOS-086163) paritaprevir (HOS-110301) ombitasvir (HOS-110300) ritonavir (HOS-084521) fesoterodine (HOS-116432) solifenacin (HOS-116433) tolvaptan (HOS-109429)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage faff2553122d6c384dc8d1a2a28fb45dbf0f436b1bcaa7a98bc5fee989b1cf04 · Zeichen 2103–2872 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132842 · Präparat HOS-097310
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin)
due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential :
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir
1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine
(methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse
reactionsevents
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of
hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of
these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) simvastatin (HOS-086158) atorvastatin (HOS-086304) lovastatin (HOS-086157) eplerenone (HOS-089050) methadone (HOS-086198) disopyramide (HOS-085595) quinidine (HOS-085593) dronedarone (HOS-086144) pimozide (HOS-085600) sertindole (HOS-085601) saquinavir (HOS-084522) ranolazine (HOS-086141) mizolastine (HOS-085609) halofantrine (HOS-085606) dabigatran (HOS-112096) triazolam (HOS-086168) midazolam (HOS-086167) alprazolam (HOS-086171) ergot alkaloids (HOS-108807) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) lurasidone (HOS-086148) quetiapine (HOS-086150) telithromycin (HOS-084523) clarithromycin (HOS-084517) felodipine (HOS-108908) nisoldipine (HOS-114251) colchicine (HOS-086147) irinotecan (HOS-112102) everolimus (HOS-086310) sirolimus (HOS-085172) vardenafil (HOS-086163) paritaprevir (HOS-110301) ombitasvir (HOS-110300) fesoterodine (HOS-116432) solifenacin (HOS-116433) tolvaptan (HOS-109429)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 0b65d259964c6f340994be44a864bad55b31283e3fc412d0d5a47323a792d889 · Zeichen 171–2105 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-132868 · Präparat HOS-097310
12
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Beta Blockers
Nadolol ↑in plasma concentrations of nadolol Careful monitoring. Dose adjustment
have been observed of nadolol may be required.
Calcium Channel
Blockers
Felodipine AUC: ↑ has been observed Contraindicated due to an increase
Nisoldipine Cmax: ↑ has been observed risk of edema and congestive heart
failure (see section 4.3).
Other dihydropyridines Potential ↑in plasma concentrations of Careful monitoring. Dose adjustment
Verapamil these drugs of dihydropyridines and verapamil
may be required.
Cardiovascular Drugs,
Miscellaneous
Ranolazine Ranolazine: Contraindicated due to the potential
AUC: ↑ 3.0 to 3.9-fold for serious cardiovascular events
including QT prolongation (see
section 4.3).
Bosentan Bosentan: Not recommended due to the
AUC: ↑ 2-fold potential for hepatic toxicity (see
Cmax: ↑ 2-fold section 4.3).
Aliskiren Aliskiren: Careful monitoring.
AUC: ↑ 1.8-fold Dose adjustment of aliskiren may be
required.
Diuretics
Eplerenone Eplerenone: Contraindicated due to the increased
AUC: ↑ 5.5-fold risk of hyperkalaemia and
hypotension (see section 4.3).
Gastrointestinal Drugs
Aprepitant Aprepitant: Careful monitoring.
AUC: ↑ 5-fold Dose adjustment of aprepitant
may be required
Domperidone Domperidone: Not recommended due to an
AUC: ↑ 3.0 fold increased risk in QT prolongation.
Cmax: ↑ 3.0 fold
Naloxegol Naloxegol Not recommended
AUC ↑ 12.9 fold
Cmax ↑ 9.6 fold
Immunosuppressants
Everolimus Everolimus: Contraindicated due to the large
Sirolimus (rapamycin) AUC: ↑ 15.3-fold increase in these medicinal products
Cmax: ↑ 4.1-fold concentrations (see section 4.3).
Sirolimus (rapamycin):
AUC: ↑ 10.9-fold
Cmax: ↑ 4.4-fold
Temsirolimus Temsirolimus: Not recommended unless necessary.
AUC: ↔ Careful monitoring and dose
Cmax: ↔ adjustment of these medicinal
Tacrolimus Ciclesonide active metabolite: products may be required.
Ciclosporine AUC: ↑ 3.5-fold
Budesonide
Ciclesonide Rest of drugs
↑in plasma concentrations of
these drugs have been observed
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nadolol (HOS-132869) calcium (HOS-085615) felodipine (HOS-108908) nisoldipine (HOS-114251) verapamil (HOS-090602) ranolazine (HOS-086141) bosentan (HOS-086291) aliskiren (HOS-086927) eplerenone (HOS-089050) aprepitant (HOS-112506) domperidone (HOS-114656) naloxegol (HOS-109428) everolimus (HOS-086310) sirolimus (HOS-085172) temsirolimus (HOS-117078) tacrolimus (HOS-085202) ciclesonide (HOS-132871) budesonide (HOS-086332)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 55c1f47059932c9461c4dbc4909ce69dab602449f5d770f01d87bd752335918f · Zeichen 23587–27472 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.